{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T07:52:17Z","timestamp":1794037937121,"version":"4.8.0"},"reference-count":269,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["69572"],"award-info":[{"award-number":["69572"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.jaut.2018.11.001","type":"journal-article","created":{"date-parts":[[2018,11,15]],"date-time":"2018-11-15T23:52:41Z","timestamp":1542325961000},"page":"1-13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":661,"special_numbering":"C","title":["Systemic lupus erythematosus: Diagnosis and clinical management"],"prefix":"10.1016","volume":"96","author":[{"given":"Andrea","family":"Fava","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1441-5373","authenticated-orcid":false,"given":"Michelle","family":"Petri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2018.11.001_bib1","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1053\/berh.2002.0259","article-title":"Epidemiology of systemic lupus erythematosus","volume":"16","author":"Petri","year":"2002","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"10.1016\/j.jaut.2018.11.001_bib2","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/art.1780380415","article-title":"The prevalence and incidence of systemic lupus erythematosus in Birmingham, England: relationship to ethnicity and country of birth","volume":"38","author":"Johnson","year":"1995","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2018.11.001_bib3","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1191\/0961203306lu2305xx","article-title":"Epidemiology of systematic lupus erythematosus: a comparison of worldwide disease burden","volume":"12","author":"Danchenko","year":"2006","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2018.11.001_bib4","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1177\/096120339500400303","article-title":"Occasional series: lupus around the World frequency of lupus in people of African origin","volume":"4","author":"Symmons","year":"1995","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2018.11.001_bib5","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.semarthrit.2008.10.007","article-title":"Understanding the epidemiology and progression of systemic lupus erythematosus","volume":"39","author":"Pons-Estel","year":"2010","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.jaut.2018.11.001_bib6","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1136\/ard.2005.040907","article-title":"Ethnicity and mortality from systemic lupus erythematosus in the US","volume":"65","author":"Krishnan","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2018.11.001_bib7","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1002\/art.38720","article-title":"Prevalence and incidence of systemic lupus erythematosus in a population-based registry of American Indian and Alaska Native people, 2007-2009","volume":"66","author":"Ferucci","year":"2014","journal-title":"Arthr. Rheumatol."},{"key":"10.1016\/j.jaut.2018.11.001_bib8","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/art.38239","article-title":"The incidence and prevalence of systemic lupus erythematosus, 2002-2004: the Georgia lupus registry","volume":"66","author":"Lim","year":"2014","journal-title":"Arthr. Rheumatol."},{"key":"10.1016\/j.jaut.2018.11.001_bib9","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/art.38238","article-title":"Population-based incidence and prevalence of systemic lupus erythematosus: the Michigan lupus epidemiology and surveillance program","volume":"66","author":"Somers","year":"2014","journal-title":"Arthr. Rheumatol."},{"key":"10.1016\/j.jaut.2018.11.001_bib10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/art.23177","article-title":"Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I","volume":"58","author":"Helmick","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2018.11.001_bib11","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/nrrheum.2016.186","article-title":"New insights into the immunopathogenesis of systemic lupus erythematosus","volume":"12","author":"Tsokos","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.jaut.2018.11.001_bib12","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jaut.2017.04.005","article-title":"Lessons learned from twins in autoimmune and chronic inflammatory diseases","volume":"83","author":"Generali","year":"2017","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2018.11.001_bib13","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jaut.2015.08.004","article-title":"Immunogenetics of systemic lupus erythematosus: a comprehensive review","volume":"64","author":"Ghodke-Puranik","year":"2015","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2018.11.001_bib14","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0192-0561(97)00061-1","article-title":"Echinacea-induced cytokine production by human macrophages","volume":"19","author":"Burger","year":"1997","journal-title":"Int. J. Immunopharmacol."},{"key":"10.1016\/j.jaut.2018.11.001_bib15","first-page":"128","article-title":"Modulation of cytokine expression by traditional medicines: a review of herbal immunomodulators","volume":"11","author":"Spelman","year":"2006","journal-title":"Altern. Med. Rev."},{"key":"10.1016\/j.jaut.2018.11.001_bib16","first-page":"265","article-title":"Antibiotic allergy in systemic lupus erythematosus: a case-control study","volume":"19","author":"Petri","year":"1992","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jaut.2018.11.001_bib17","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1002\/art.20049","article-title":"Cigarette smoking and the risk of systemic lupus erythematosus: a meta-analysis","volume":"50","author":"Costenbader","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2018.11.001_bib18","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/art.1780370109","article-title":"Increased antiretroviral antibody reactivity in sera from a defined population of patients with systemic lupus erythematosus: correlation with autoantibodies and clinical manifestations","volume":"37","author":"Blomberg","year":"1994","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2018.11.001_bib19","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s11926-004-0011-6","article-title":"Occupational and environmental exposures as risk factors for systemic lupus erythematosus","volume":"6","author":"Cooper","year":"2004","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.jaut.2018.11.001_bib20","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/1529-0131(200105)44:5<1122::AID-ANR193>3.0.CO;2-D","article-title":"Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure","volume":"44","author":"James","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2018.11.001_bib21","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1002\/art.10368","article-title":"Occupational exposure to crystalline silica and risk of systemic lupus erythematosus: a population-based, case-control study in the southeastern United States","volume":"46","author":"Parks","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2018.11.001_bib22","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.autrev.2016.09.020","article-title":"Mercury as an environmental stimulus in the development of autoimmunity \u2013 a systematic review","volume":"16","author":"Crowe","year":"2017","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2018.11.001_bib23","article-title":"Anti-dsDNA antibodies in laboratory workers handling blood from patients with systemic lupus erythematosus","volume":"19","author":"Zarmbinski","year":"1992","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jaut.2018.11.001_bib24","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1191\/0961203303lu1039oa","article-title":"Pet dogs owned by lupus patients are at a higher risk of developing lupus","volume":"13","author":"Chiou","year":"2004","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2018.11.001_bib25","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1001\/jama.2018.7028","article-title":"Association of stress-related disorders with subsequent autoimmune disease","volume":"319","author":"Song","year":"2018","journal-title":"Jama"},{"key":"10.1016\/j.jaut.2018.11.001_bib26","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1002\/art.40222","article-title":"Association of trauma and posttraumatic stress disorder with incident systemic lupus erythematosus in a longitudinal cohort of women","volume":"69","author":"Roberts","year":"2017","journal-title":"Arthr. Rheumatol. (Hoboken, N.J.)."},{"key":"10.1016\/j.jaut.2018.11.001_bib27","series-title":"Etiology and Pathogenesis of Systemic Lupus Erythematosus","author":"Crow","year":"2017"},{"key":"10.1016\/j.jaut.2018.11.001_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01088","article-title":"Aberrant T cell signaling and subsets in systemic lupus erythematosus","volume":"9","author":"Katsuyama","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2018.11.001_bib29","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1073\/pnas.0337679100","article-title":"Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus","volume":"100","author":"Baechler","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jaut.2018.11.001_bib30","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1084\/jem.20021553","article-title":"Interferon and granulopoiesis signatures in systemic lupus erythematosus blood","volume":"197","author":"Bennett","year":"2003","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jaut.2018.11.001_bib31","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1002\/art.20798","article-title":"Coordinate overexpression of interferon-?-induced genes in systemic lupus erythematosus","volume":"50","author":"Kirou","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2018.11.001_bib32","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.4049\/jimmunol.1201719","article-title":"Neutrophil extracellular traps: double-edged swords of innate immunity","volume":"189","author":"Kaplan","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2018.11.001_bib33","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001201","article-title":"Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus","volume":"3","author":"Garcia-Romo","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jaut.2018.11.001_bib34","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001180","article-title":"Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA peptide complexes in systemic lupus erythematosus","volume":"3","author":"Lande","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jaut.2018.11.001_bib35","doi-asserted-by":"crossref","first-page":"9813","DOI":"10.1073\/pnas.0909927107","article-title":"Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis","volume":"107","author":"Hakkim","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jaut.2018.11.001_bib36","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s13075-015-0726-y","article-title":"A subset of patients with systemic lupus erythematosus fails to degrade DNA from multiple clinically relevant sources","volume":"17","author":"Leffler","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2018.11.001_bib37","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1084\/jem.179.4.1317","article-title":"Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes","volume":"179","author":"a Casciola-Rosen","year":"1994","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jaut.2018.11.001_bib38","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1073\/pnas.93.4.1624","article-title":"Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: implications for coagulation events and antigenic spread in systemic lupus erythematosus","volume":"93","author":"Casciola-Rosen","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jaut.2018.11.001_bib39","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.autrev.2008.12.012","article-title":"Clinic and pathophysiology of photosensitivity in lupus erythematosus","volume":"8","author":"Lehmann","year":"2009","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2018.11.001_bib40","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/nature09102","article-title":"TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus","volume":"465","author":"Guiducci","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jaut.2018.11.001_bib41","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.4049\/jimmunol.180.4.2329","article-title":"C1q binds phosphatidylserine and likely acts as a multiligand-bridging molecule in apoptotic cell recognition","volume":"180","author":"Paidassi","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2018.11.001_bib42","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/nri2849","article-title":"The importance of natural IgM: scavenger, protector and regulator","volume":"10","author":"Ehrenstein","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jaut.2018.11.001_bib43","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJM198007033030107","article-title":"A genetic defect of the C1q subcomponent of complement associated with childhood (immune complex) nephritis","volume":"303","author":"Thompson","year":"1980","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2018.11.001_bib44","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.cell.2016.05.034","article-title":"Digestion of chromatin in apoptotic cell microparticles prevents autoimmunity","volume":"166","author":"Sisirak","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.jaut.2018.11.001_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11926-016-0621-9","article-title":"Monogenic lupus","volume":"18","author":"Lo","year":"2016","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.jaut.2018.11.001_bib46","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/art.1780251101","article-title":"The 1982 revised criteria for the classification of systemic lupus erythematosus","volume":"25","author":"Tan","year":"1982","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2018.11.001_bib47","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2018.11.001_bib48","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/art.34473","article-title":"Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus","volume":"64","author":"Petri","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2018.11.001_bib49","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/acr.23317","article-title":"Developing and refining new candidate criteria for systemic lupus erythematosus classification: an international collaboration","volume":"70","author":"Tedeschi","year":"2018","journal-title":"Arthritis Care Res."},{"issue":"suppl","key":"10.1016\/j.jaut.2018.11.001_bib50","article-title":"Validation of proposed EULAR\/acr SLE classification criteria versus SLICC SLE classification criteria","volume":"70","author":"Petri","year":"2018","journal-title":"Arthr. Rheumatol."},{"key":"10.1016\/j.jaut.2018.11.001_bib51","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.autrev.2018.01.007","article-title":"Performance of the 2012 Systemic Lupus International Collaborating Clinics classification criteria versus the 1997 American College of Rheumatology classification criteria in adult and juvenile systemic lupus erythematosus. A systematic review and meta-an","volume":"17","author":"Hartman","year":"2018","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2018.11.001_bib52","series-title":"Dubois' Lupus Erythematosus and Related Syndromes","author":"Wallace","year":"2012"},{"key":"10.1016\/j.jaut.2018.11.001_bib53","series-title":"Kelley and Firestein's Textbook of Rheumatology","author":"Firestein","year":"2016"},{"key":"10.1016\/j.jaut.2018.11.001_bib54","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40257-016-0173-9","article-title":"Cutaneous lupus erythematosus: an update on pathogenesis, diagnosis and treatment","volume":"17","author":"Hejazi","year":"2016","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.jaut.2018.11.001_bib55","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2165\/11310780-000000000-00000","article-title":"Cutaneous lupus erythematosus: issues in diagnosis and treatment","volume":"10","author":"Walling","year":"2009","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.jaut.2018.11.001_bib56","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1365-2133.1997.tb03655.x","article-title":"Photosensitivity in lupus erythematosus, UV photoprovocation results compared with history of photosensitivity and clinical findings","volume":"136","author":"Hasan","year":"1997","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jaut.2018.11.001_bib57","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1046\/j.1365-2133.2003.05379.x","article-title":"Photosensitivity in patients with lupus erythematosus: a clinical and photobiological study of 100 patients using a prolonged phototest protocol","volume":"149","author":"Sanders","year":"2003","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jaut.2018.11.001_bib58","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1067\/mjd.2001.114589","article-title":"Phototesting in lupus erythematosus: a 15-year experience","volume":"45","author":"Kuhn","year":"2001","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jaut.2018.11.001_bib59","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/0961203311426568","article-title":"Environment and lupus-related diseases","volume":"21","author":"Zandman-Goddard","year":"2012","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2018.11.001_bib60","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/00000441-197404000-00005","article-title":"Lupus hair","volume":"267","author":"Alarcon Segovia","year":"1974","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/j.jaut.2018.11.001_bib61","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000086440","article-title":"Association between discoid lupus erythematosus and cigarette smoking: a case-control study","volume":"211","author":"Miot","year":"2005","journal-title":"Dermatology"},{"key":"10.1016\/j.jaut.2018.11.001_bib62","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1177\/0961203314559630","article-title":"Smoking is highly associated with discoid lupus erythematosus and lupus erythematosus tumidus: analysis of 405 patients","volume":"24","author":"B\u00f6ckle","year":"2015","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2018.11.001_bib63","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1001\/archdermatol.2011.342","article-title":"Impact of smoking in cutaneous lupus erythematosus","volume":"148","author":"Piette","year":"2012","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.jaut.2018.11.001_bib64","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jaad.2014.12.025","article-title":"Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta-analysis of the literature","volume":"72","author":"Chasset","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jaut.2018.11.001_bib65","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/art.1790080305","article-title":"Musculoskeletal complications of systemic lupus erythematosus in the Hopkins Lupus Cohort: an update","volume":"8","author":"Petri","year":"1995","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.jaut.2018.11.001_bib66","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.berh.2009.04.003","article-title":"Lupus arthritis","volume":"23","author":"Grossman","year":"2009","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"10.1016\/j.jaut.2018.11.001_bib67","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1177\/0961203314540967","article-title":"Anti-cyclic citrullinated peptide antibody as a marker of erosive arthritis in patients with systemic lupus erythematosus: a systematic review and meta-analysis","volume":"23","author":"Budhram","year":"2015","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2018.11.001_bib68","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1007\/s00330-015-3670-y","article-title":"Ultrasound evaluation of joints in systemic lupus erythematosus: a systematic review","volume":"25","author":"Lins","year":"2015","journal-title":"Eur. Radiol."},{"key":"10.1016\/j.jaut.2018.11.001_bib69","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/art.10753","article-title":"Jaccoud's arthropathy in systemic lupus erythematosus: differentiation of deforming and erosive patterns by magnetic resonance imaging","volume":"48","author":"Ostendorf","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2018.11.001_bib70","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2018-000264","article-title":"Measuring lupus arthritis activity using contrasted high-field MRI. Associations with clinical measures of disease activity and novel patterns of disease","volume":"5","author":"Zollars","year":"2018","journal-title":"Lupus Sci. Med."},{"key":"10.1016\/j.jaut.2018.11.001_bib71","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3899\/jrheum.080212","article-title":"Fibromyalgia, systemic lupus erythematosus (SLE), and evaluation of SLE activity","volume":"36","author":"Wolfe","year":"2008","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jaut.2018.11.001_bib72","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.3899\/jrheum.091366","article-title":"Depression and cognitive impairment in newly diagnosed systemic lupus erythematosus","volume":"37","author":"Petri","year":"2010","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jaut.2018.11.001_bib73","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1191\/0961203302lu158oa","article-title":"Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis","volume":"11","author":"Bastian","year":"2002","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2018.11.001_bib74","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1002\/art.21955","article-title":"Mortality in systemic lupus erythematosus","volume":"54","author":"Bernatsky","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2018.11.001_bib75","first-page":"1563","article-title":"Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure","volume":"33","author":"Faurschou","year":"2006","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jaut.2018.11.001_bib76","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3899\/jrheum.110532","article-title":"Frequency of class III and IV nephritis in systemic lupus erythematosus without clinical renal involvement: an analysis of predictive measures","volume":"39","author":"Wakasugi","year":"2012","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jaut.2018.11.001_bib77","first-page":"332","article-title":"Renal biopsy in lupus patients with low levels of proteinuria","volume":"34","author":"Christopher-Stine","year":"2007","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jaut.2018.11.001_bib78","first-page":"1557","article-title":"Urine protein-to-creatinine ratio is a reliable measure of proteinuria in lupus nephritis","volume":"31","author":"Christopher-Stine","year":"2004","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jaut.2018.11.001_bib79","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.2215\/CJN.01910213","article-title":"Elevated subclinical double-stranded DNA antibodies and future proliferative lupus nephritis","volume":"8","author":"Olson","year":"2013","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.jaut.2018.11.001_bib80","article-title":"Anti-C1q antibodies in systemic lupus erythematosus","volume":"24","author":"Orbai","year":"2014","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2018.11.001_bib81","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1177\/0961203311411597","article-title":"Anti-C1q antibodies have higher correlation with flares of lupus nephritis than other serum markers","volume":"20","author":"Akhter","year":"2011","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2018.11.001_bib82","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1177\/0961203316645205","article-title":"Anti-C1q in systemic lupus erythematosus","volume":"25","author":"Stojan","year":"2016","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2018.11.001_bib83","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1523-1755.2004.00443.x","article-title":"The classification of glomerulonephritis in systemic lupus erythematosus revisited","volume":"65","author":"Weening","year":"2004","journal-title":"Kidney Int."},{"key":"10.1016\/j.jaut.2018.11.001_bib84","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/rheumatology\/kep256","article-title":"Lupus podocytopathy","volume":"48","author":"Shea-Simonds","year":"2009","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2018.11.001_bib85","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/00005792-199709000-00003","article-title":"Renal vascular lesions in lupus nephritis","volume":"76","author":"Descombes","year":"1997","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jaut.2018.11.001_bib86","doi-asserted-by":"crossref","first-page":"914","DOI":"10.2215\/CJN.11751111","article-title":"Collapsing glomerulopathy in 19 patients with systemic lupus erythematosus or Lupus-like disease","volume":"7","author":"Salvatore","year":"2012","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.jaut.2018.11.001_bib87","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/1529-0131(200110)45:5<419::AID-ART360>3.0.CO;2-X","article-title":"Validity of the new American College of Rheumatology criteria for neuropsychiatric lupus syndromes: a population\u2010based evaluation","volume":"45","author":"Ainiala","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2018.11.001_bib88","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/art.34473","article-title":"Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus","volume":"64","author":"Petri","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2018.11.001_bib89","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1002\/1529-0131(199910)42:10<2026::AID-ANR2>3.0.CO;2-J","article-title":"Neuroimaging in neuropsychiatric systemic lupus erythematosus","volume":"42","author":"Sibbitt","year":"1999","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2018.11.001_bib90","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1002\/art.24937","article-title":"Distinct subtypes of myelitis in systemic lupus erythematosus","volume":"60","author":"Birnbaum","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2018.11.001_bib91","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1007\/BF00856812","article-title":"Gadolinium-enhanced magnetic resonance imaging of the central nervous system in systemic lupus erythematosus","volume":"239","author":"Miller","year":"1992","journal-title":"J. Neurol."},{"key":"10.1016\/j.jaut.2018.11.001_bib92","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/art.1780380615","article-title":"Spin-spin relaxation of brain tissues in systemic lupus erythematosus","volume":"38","author":"Sibbitt","year":"1995","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2018.11.001_bib93","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0002-9343(99)80135-1","article-title":"Neuropsychiatric lupus erythematosus: a 10-year prospective study on the value of diagnostic tests","volume":"99","author":"West","year":"1995","journal-title":"Am. J. Med."},{"key":"10.1016\/j.jaut.2018.11.001_bib94","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/00005053-198606000-00008","article-title":"Prevalence of cognitive impairment in systemic lupus erythematosus","volume":"174","author":"Carbotte","year":"1986","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.jaut.2018.11.001_bib95","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/art.20692","article-title":"Reliability and validity of the proposed American College of Rheumatology neuropsychological battery for systemic lupus erythematosus","volume":"51","author":"Kozora","year":"2004","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.jaut.2018.11.001_bib96","first-page":"1776","article-title":"Cognitive function in a systemic lupus erythematosus inception cohort","volume":"35","author":"Petri","year":"2008","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jaut.2018.11.001_bib97","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.3899\/jrheum.091366","article-title":"Depression and cognitive impairment in newly diagnosed systemic lupus erythematosus","volume":"37","author":"Petri","year":"2010","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jaut.2018.11.001_bib98","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/416603a","article-title":"Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors","volume":"416","author":"Leadbetter","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.jaut.2018.11.001_bib99","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1172\/JCI23025","article-title":"Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9","volume":"115","author":"Means","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jaut.2018.11.001_bib100","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.4049\/jimmunol.1000702","article-title":"Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines","volume":"186","author":"Kuznik","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2018.11.001_bib101","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1002\/art.22157","article-title":"Antimalarial agents: closing the gate on toll-like receptors?","volume":"54","author":"Lafyatis","year":"2006","journal-title":"Arthritis Rheum."},{"issue":"Suppl 1","key":"10.1016\/j.jaut.2018.11.001_bib102","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1177\/0961203396005001051","article-title":"Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis","volume":"5","author":"Petri","year":"1996","journal-title":"Lupus"},{"issue":"Suppl 1","key":"10.1016\/j.jaut.2018.11.001_bib103","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1177\/0961203396005001031","article-title":"Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development","volume":"5","author":"Fox","year":"1996","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2018.11.001_bib104","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1191\/0961203306lu2299oa","article-title":"Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients","volume":"15","author":"Wozniacka","year":"2006","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2018.11.001_bib105","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.4049\/jimmunol.1402793","article-title":"Cutting edge: antimalarial drugs inhibit IFN-\u03b2 production through blockade of cyclic GMP-AMP synthase\u2013DNA interaction","volume":"194","author":"An","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2018.11.001_bib106","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1136\/ard.2006.068676","article-title":"Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L)","volume":"66","author":"Alarc\u00f3n","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2018.11.001_bib107","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1177\/0961203306071872","article-title":"Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus","volume":"15","author":"Ruiz-Irastorza","year":"2006","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2018.11.001_bib108","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/ard.2008.101766","article-title":"Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review","volume":"69","author":"Ruiz-Irastorza","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2018.11.001_bib109","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1177\/0961203317739129","article-title":"Effect of immunosuppressive therapies on survival of systemic lupus erythematosus: a propensity score analysis of a longitudinal cohort","volume":"27","author":"Mok","year":"2018","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2018.11.001_bib110","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1056\/NEJM199101173240303","article-title":"A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus","volume":"324","author":"Canadian Hydroxychloroquine Study Group","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2018.11.001_bib111","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1002\/art.21039","article-title":"Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual","volume":"52","author":"Fessler","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2018.11.001_bib112","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.3899\/jrheum.161351","article-title":"Longterm hydroxychloroquine therapy and low-dose aspirin may have an additive effectiveness in the primary prevention of cardiovascular events in patients with systemic lupus erythematosus","volume":"44","author":"Fasano","year":"2017","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jaut.2018.11.001_bib113","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1191\/0961203306lu2313oa","article-title":"Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis","volume":"15","author":"Kasitanon","year":"2006","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2018.11.001_bib114","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1136\/annrheumdis-2011-201089","article-title":"Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study","volume":"71","author":"Hanly","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2018.11.001_bib115","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1136\/ard.2007.077594","article-title":"Seizures in patients with systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA LIV)","volume":"67","author":"Andrade","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2018.11.001_bib116","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1177\/0961203309104392","article-title":"Time to neuropsychiatric damage occurrence in LUMINA (LXVI): a multi-ethnic lupus cohort","volume":"18","author":"Gonz\u00e1lez","year":"2009","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2018.11.001_bib117","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1365-2133.1992.tb14851.x","article-title":"Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine","volume":"127","author":"Ruzicka","year":"1992","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jaut.2018.11.001_bib118","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1016\/j.jaad.2010.06.018","article-title":"Cutaneous lupus erythematosus: update of therapeutic options: Part i","volume":"65","author":"Kuhn","year":"2011","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jaut.2018.11.001_bib119","first-page":"1457","article-title":"Comparison of hydroxychloroquine and placebo in the treatment of the arthropathy of mild systemic lupus erythematosus","volume":"21","author":"Williams","year":"1994","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jaut.2018.11.001_bib120","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/1756-185X.13159","article-title":"Favorable effects of hydroxychloroquine on serum low density lipid in patients with systemic lupus erythematosus: a systematic review and meta-analysis","volume":"21","author":"Babary","year":"2018","journal-title":"Int. J. Rheum. Dis."},{"key":"10.1016\/j.jaut.2018.11.001_bib121","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/0002-9343(94)90151-1","article-title":"Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis","volume":"96","author":"Petri","year":"1994","journal-title":"Am. J. Med."},{"key":"10.1016\/j.jaut.2018.11.001_bib122","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1177\/0961203312450084","article-title":"Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect","volume":"21","author":"Cairoli","year":"2012","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2018.11.001_bib123","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1007\/s00125-015-3689-2","article-title":"Antidiabetogenic effects of hydroxychloroquine on insulin sensitivity and beta cell function: a randomised trial","volume":"58","author":"Wasko","year":"2015","journal-title":"Diabetologia"},{"key":"10.1016\/j.jaut.2018.11.001_bib124","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3109\/03009749609069986","article-title":"Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective","volume":"25","author":"Petri","year":"1996","journal-title":"Scand. J. Rheumatol."},{"key":"10.1016\/j.jaut.2018.11.001_bib125","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1177\/096120339600500524","article-title":"In vivo models of thrombosis for the antiphospholipid syndrome","volume":"5","author":"Pierangeli","year":"1996","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2018.11.001_bib126","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1191\/0961203305lu2039oa","article-title":"Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosus","volume":"14","author":"Mok","year":"2005","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2018.11.001_bib127","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.3899\/jrheum.150671","article-title":"Risk of serious infection for patients with systemic lupus erythematosus starting glucocorticoids with or without antimalarials","volume":"43","author":"Herrinton","year":"2016","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jaut.2018.11.001_bib128","doi-asserted-by":"crossref","first-page":"80461","DOI":"10.18632\/oncotarget.19057","article-title":"Hydroxychloroquine and risk of cancer in patients with primary Sj\u00f6gren syndrome: propensity score matched landmark analysis","volume":"8","author":"Fang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jaut.2018.11.001_bib129","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/acr.20133","article-title":"Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus","volume":"62","author":"Wolfe","year":"2010","journal-title":"Arthritis Care Res. (Hoboken)."},{"key":"10.1016\/j.jaut.2018.11.001_bib130","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ophtha.2010.11.017","article-title":"American Academy of Ophthalmology, Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy","volume":"118","author":"Marmor","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jaut.2018.11.001_bib131","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.abb.2012.04.001","article-title":"Where is the vitamin D receptor?","volume":"523","author":"Wang","year":"2012","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.jaut.2018.11.001_bib132","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1124\/jpet.107.127209","article-title":"Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1\/Th17 to a Th2 and regulatory T cell profile","volume":"324","author":"Daniel","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jaut.2018.11.001_bib133","doi-asserted-by":"crossref","first-page":"5207","DOI":"10.1073\/pnas.0711558105","article-title":"The vitamin D receptor is required for iNKT cell development","volume":"105","author":"Yu","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jaut.2018.11.001_bib134","first-page":"22","article-title":"Antifibrotic vitamin D analogs","volume":"123","author":"V Bonventre","year":"2013"},{"issue":"suppl","key":"10.1016\/j.jaut.2018.11.001_bib135","article-title":"Kidney and skin single-cell RNA sequencing in lupus nephritis provides mechanistic insights and novel potential biomarkers","volume":"69","author":"Der","year":"2017","journal-title":"Arthr. Rheumatol."},{"key":"10.1016\/j.jaut.2018.11.001_bib136","first-page":"1","article-title":"Chronic Vitamin D deficiency induces lung fibrosis through activation of the renin-angiotensin system","volume":"7","author":"Shi","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jaut.2018.11.001_bib137","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/rheumatology\/ken121","article-title":"Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences","volume":"47","author":"Ruiz-irastorza","year":"2008","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2018.11.001_bib138","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s12016-013-8361-3","article-title":"The implication of vitamin D and autoimmunity: a comprehensive review","volume":"45","author":"Yang","year":"2013","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.jaut.2018.11.001_bib139","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1586\/eci.13.19","article-title":"Vitamin D and systemic lupus erythematosus: an update","volume":"9","author":"Mok","year":"2013","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.jaut.2018.11.001_bib140","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1136\/ard.2009.120329","article-title":"Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D?","volume":"69","author":"Amital","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2018.11.001_bib141","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1177\/0961203312446386","article-title":"Vitamin D and antiphospholipid syndrome","volume":"21","author":"Andreoli","year":"2012","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2018.11.001_bib142","doi-asserted-by":"crossref","first-page":"307","DOI":"10.4081\/reumatismo.2012.307","article-title":"Low levels of vitamin D are common in primary antiphospholipid syndrome with thrombotic disease","volume":"64","author":"Piantoni","year":"2012","journal-title":"Reumatismo"},{"key":"10.1016\/j.jaut.2018.11.001_bib143","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1002\/art.37953","article-title":"Vitamin D in systemic lupus erythematosus: modest association with disease activity and the urine protein-to-creatinine ratio","volume":"65","author":"Petri","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2018.11.001_bib144","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/acr.22621","article-title":"Vitamin D supplementation in adolescents and young adults with juvenile systemic lupus erythematosus for improvement in disease activity and fatigue scores: a randomized, double-blind, placebo-controlled trial","volume":"68","author":"Lima","year":"2016","journal-title":"Arthritis Care Res. (Hoboken)."},{"key":"10.1016\/j.jaut.2018.11.001_bib145","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jaut.2016.06.010","article-title":"Immunomodulators in SLE: clinical evidence and immunologic actions","volume":"74","author":"Durcan","year":"2016","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2018.11.001_bib146","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1749-6632.1995.tb17369.x","article-title":"DHEA and peripheral androgen and estrogen formation: intracrinology","volume":"774","author":"Labrie","year":"1995","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jaut.2018.11.001_bib147","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1002\/art.11105","article-title":"Sex hormones and systemic lupus erythematosus: review and meta-analysis","volume":"48","author":"McMurray","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2018.11.001_bib148","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/art.1780300301","article-title":"Low plasma androgens in women with systemic lupus erythematosus","volume":"30","author":"Lahita","year":"1987","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2018.11.001_bib149","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1172\/JCI111929","article-title":"Prevention of autoantibody formation and prolonged survival in New Zealand Black\/New Zealand White F1mice fed dehydroisoandrosterone","volume":"75","author":"Lucas","year":"1985","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jaut.2018.11.001_bib150","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1136\/ard.2003.016576","article-title":"Dehydroepiandrosterone suppresses interleukin 10 synthesis in women with systemic lupus erythematosus","volume":"63","author":"Chang","year":"2004","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2018.11.001_bib151","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1055\/s-2004-861553","article-title":"Adrenal androgens and the immune system","volume":"22","author":"Chen","year":"2004","journal-title":"Semin. Reprod. Med."},{"key":"10.1016\/j.jaut.2018.11.001_bib152","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2174\/1568010054022079","article-title":"Dehydroepiandrosterone, dehydroepiandrosterone sulfate and related steroids: their role in inflammatory, allergic and immunological disorders","volume":"4","author":"Dillon","year":"2005","journal-title":"Curr. Drug Targets Inflamm. Allergy"},{"key":"10.1016\/j.jaut.2018.11.001_bib153","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1002\/art.10364","article-title":"Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial","volume":"46","author":"Petri","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2018.11.001_bib154","first-page":"1567","article-title":"Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus receiving chronic glucocorticoid therapy","volume":"35","author":"Sanchez-Guerrero","year":"2008","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jaut.2018.11.001_bib155","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nri.2017.1","article-title":"Immune regulation by glucocorticoids","volume":"17","author":"Cain","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jaut.2018.11.001_bib156","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/acr.21664","article-title":"American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis","volume":"64","author":"Hahn","year":"2012","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.jaut.2018.11.001_bib157","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1136\/annrheumdis-2012-201940","article-title":"Joint european league against rheumatism and european renal association-european dialysis and transplant association (EULAR\/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis","volume":"71","author":"Bertsias","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2018.11.001_bib158","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1136\/annrheumdis-2012-202844","article-title":"Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids","volume":"72","author":"Condon","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"suppl","key":"10.1016\/j.jaut.2018.11.001_bib159","article-title":"Speed of remission with the use of voclosporin, MMF and low dose steroids: results of a global lupus nephritis study [abstract]","volume":"68","author":"Dooley","year":"2016","journal-title":"Arthr. Rheumatol."},{"key":"10.1016\/j.jaut.2018.11.001_bib160","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.3899\/jrheum.160041","article-title":"Treatments for lupus nephritis: a systematic review and network metaanalysis","volume":"43","author":"Singh","year":"2016","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jaut.2018.11.001_bib161","first-page":"1955","article-title":"Accrual of organ damage over time in patients with systemic lupus erythematosus","volume":"30","author":"Gladman","year":"2003","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jaut.2018.11.001_bib162","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/aje\/kws130","article-title":"Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus","volume":"176","author":"Magder","year":"2012","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.jaut.2018.11.001_bib163","doi-asserted-by":"crossref","first-page":"560","DOI":"10.3899\/jrheum.080828","article-title":"Prednisone, lupus activity, and permanent organ damage","volume":"36","author":"Thamer","year":"2009","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jaut.2018.11.001_bib164","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1002\/1529-0131(200008)43:8<1801::AID-ANR16>3.0.CO;2-O","article-title":"Damage in systemic lupus erythematosus and its association with corticosteroids","volume":"43","author":"Zonana-Nacach","year":"2000","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2018.11.001_bib165","first-page":"57","article-title":"Flares in Lupus: outcome Assessment Trial (FLOAT), a comparison between oral methylprednisolone and intramuscular triamcinolone","volume":"33","author":"Danowski","year":"2006","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jaut.2018.11.001_bib166","series-title":"Syst. Lupus Erythematosus Basic, Appl. Clin. Asp.","article-title":"Cytotoxic-immunosuppressive drug treatment","author":"Frangou","year":"2016"},{"key":"10.1016\/j.jaut.2018.11.001_bib167","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/art.1780170602","article-title":"A double-blind controlled trial comparing cyclophosphamide, azathioprine and placebo in the treatment of lupus glomerulonephritis","volume":"17","author":"Steinberg","year":"1974","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2018.11.001_bib168","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJM198603063141004","article-title":"Therapy of lupus nephritis","volume":"314","author":"Austin","year":"1986","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2018.11.001_bib169","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJM198806023182203","article-title":"Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus","volume":"318","author":"McCune","year":"1988","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2018.11.001_bib170","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1136\/ard.2006.057885","article-title":"Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system","volume":"66","author":"Tokunaga","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2018.11.001_bib171","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s40265-015-0534-3","article-title":"Management of neuropsychiatric systemic lupus erythematosus: current approaches and future perspectives","volume":"76","author":"Magro-Checa","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.jaut.2018.11.001_bib172","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/ndt\/gfw068","article-title":"Con: cyclophosphamide for the treatment of lupus nephritis","volume":"31","author":"Mok","year":"2016","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.jaut.2018.11.001_bib173","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1172\/JCI16432","article-title":"CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes","volume":"111","author":"Tiede","year":"2003","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jaut.2018.11.001_bib174","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/art.1780180106","article-title":"Long-term maintenance therapy with azathioprine in systemic lupus erythematosus","volume":"18","author":"Ginzler","year":"1975","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2018.11.001_bib175","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/art.1780140511","article-title":"Azathioprine in the treatment of systemic lupus erythematosus. A controlled study","volume":"14","author":"Sztejnbok","year":"1971","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2018.11.001_bib176","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/sj.ki.5001630","article-title":"Azathioprine\/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial","volume":"70","author":"Grootscholten","year":"2006","journal-title":"Kidney Int."},{"key":"10.1016\/j.jaut.2018.11.001_bib177","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/art.22449","article-title":"Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis","volume":"56","author":"Grootscholten","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2018.11.001_bib178","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1056\/NEJMoa1014460","article-title":"Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis","volume":"365","author":"Dooley","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2018.11.001_bib179","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1136\/ard.2010.131995","article-title":"Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial","volume":"69","author":"Houssiau","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2018.11.001_bib180","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/rheumatology\/kep396","article-title":"The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE","volume":"49","author":"Griffiths","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaut.2018.11.001_bib181","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1136\/annrheumdis-2016-210882","article-title":"Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial","volume":"76","author":"Ordi-Ros","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2018.11.001_bib182","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.rdc.2016.12.009","article-title":"Systemic lupus erythematosus and pregnancy","volume":"43","author":"Lateef","year":"2017","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"10.1016\/j.jaut.2018.11.001_bib183","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1111\/j.1572-0241.2006.00538.x","article-title":"Azathioprine use during pregnancy: unexpected intrauterine exposure to metabolites","volume":"101","author":"De Boer","year":"2006","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.jaut.2018.11.001_bib184","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nrrheum.2016.175","article-title":"Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers","volume":"12","author":"Brown","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.jaut.2018.11.001_bib185","first-page":"1","article-title":"Diagnosis and treatment of systemic lupus erythematosus","volume":"2","author":"Miescher","year":"1965","journal-title":"Semin. Hematol."},{"issue":"3","key":"10.1016\/j.jaut.2018.11.001_bib186","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/0961203313519159","article-title":"Methotrexate in systemic lupus erythematosus: a systematic review of its efficacy","volume":"23","author":"Sakthiswary R","year":"2014","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2018.11.001_bib187","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1002\/art.24068","article-title":"Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial","volume":"59","author":"Fortin","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2018.11.001_bib188","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1177\/096120330501400102","article-title":"Mechanisms of action of mycophenolate mofetil","volume":"14","author":"Allison","year":"2005","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2018.11.001_bib189","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1056\/NEJM200010193431604","article-title":"Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis","volume":"343","author":"Chan","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2018.11.001_bib190","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa043731","article-title":"Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis","volume":"353","author":"Ginzler","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2018.11.001_bib191","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1681\/ASN.2008101028","article-title":"Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis","volume":"20","author":"Appel","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.jaut.2018.11.001_bib192","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002922.pub4","article-title":"Immunosuppressive treatment for proliferative lupus nephritis","author":"Tunnicliffe","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jaut.2018.11.001_bib193","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1080\/03009740701607042","article-title":"Mycophenolate mofetil for non-renal manifestations of systemic lupus erythematosus: a systematic review","volume":"36","author":"Mok","year":"2007","journal-title":"Scand. J. Rheumatol."},{"key":"10.1016\/j.jaut.2018.11.001_bib194","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/art.25052","article-title":"Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial","volume":"62","author":"Ginzler","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2018.11.001_bib195","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.berh.2017.09.010","article-title":"Calcineurin inhibitors in systemic lupus erythematosus","volume":"31","author":"Mok","year":"2017","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"10.1016\/j.jaut.2018.11.001_bib196","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1046\/j.1523-1755.2002.00259.x","article-title":"FK506 ameliorates proteinuria and glomerular lesions induced by anti-Thy 1.1 monoclonal antibody 1-22-3","volume":"61","author":"Ikezumi","year":"2002","journal-title":"Kidney Int."},{"key":"10.1016\/j.jaut.2018.11.001_bib197","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0132724","article-title":"Tacrolimus protects podocytes from injury in lupus nephritis partly by stabilizing the cytoskeleton and inhibiting podocyte apoptosis","volume":"10","author":"Liao","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.jaut.2018.11.001_bib198","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/nm.1857","article-title":"The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A","volume":"14","author":"Faul","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.jaut.2018.11.001_bib199","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/ndt\/gfh739","article-title":"Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results","volume":"20","author":"Kr\u00e4mer","year":"2005","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.jaut.2018.11.001_bib200","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/ndt\/gfr484","article-title":"Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis","volume":"27","author":"Li","year":"2012","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.jaut.2018.11.001_bib201","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1053\/j.ajkd.2010.08.036","article-title":"Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: a multicenter randomized clinical trial","volume":"57","author":"Chen","year":"2011","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.jaut.2018.11.001_bib202","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1177\/0961203310371155","article-title":"Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study","volume":"19","author":"Z\u00e1vada","year":"2010","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2018.11.001_bib203","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/0961203313511555","article-title":"Extended follow-up of the CYCLOFA-LUNE trial comparing two sequential induction and maintenance treatment regimens for proliferative lupus nephritis based either on cyclophosphamide or on cyclosporine A","volume":"23","author":"Z\u00e1vada","year":"2014","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2018.11.001_bib204","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.autrev.2015.09.006","article-title":"Tacrolimus use in lupus nephritis: a systematic review and meta-analysis","volume":"15","author":"Hannah","year":"2016","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2018.11.001_bib205","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/annrheumdis-2014-206456","article-title":"Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up","volume":"75","author":"Mok","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2018.11.001_bib206","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1177\/0961203310365714","article-title":"Combination therapy of mycophenolate mofetil and tacrolimus in lupus nephritis","volume":"19","author":"Lanata","year":"2010","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2018.11.001_bib207","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1093\/ndt\/gfq322","article-title":"Long-term outcomes - mycophenolate mofetil treatment for lupus nephritis with addition of tacrolimus for resistant cases","volume":"25","author":"Cort\u00e9s-Hern\u00e1ndez","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.jaut.2018.11.001_bib208","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1177\/0961203313502864","article-title":"Combined low-dose mycophenolate mofetil and tacrolimus for lupus nephritis with suboptimal response to standard therapy: a 12-month prospective study","volume":"22","author":"Mok","year":"2013","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2018.11.001_bib209","doi-asserted-by":"crossref","first-page":"18","DOI":"10.7326\/M14-1030","article-title":"Multitarget therapy for induction treatment of lupus nephritis: a randomized trial","volume":"162","author":"Liu","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jaut.2018.11.001_bib210","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2215\/CJN.02271205","article-title":"A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years","volume":"1","author":"Moroni","year":"2006","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.jaut.2018.11.001_bib211","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1177\/0961203312442259","article-title":"Outcomes of maintenance therapy with tacrolimus versus azathioprine for active lupus nephritis: a multicenter randomized clinical trial","volume":"21","author":"Chen","year":"2012","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2018.11.001_bib212","first-page":"147","article-title":"Cyclosporine treatment of lupus membranous nephropathy","volume":"42","author":"Radhakrishnan","year":"1994","journal-title":"Clin. Nephrol."},{"key":"10.1016\/j.jaut.2018.11.001_bib213","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1440-1797.2012.01574.x","article-title":"Pilot 24 month study to compare mycophenolate mofetil and tacrolimus in the treatment of membranous lupus nephritis with nephrotic syndrome","volume":"17","author":"Yap","year":"2012","journal-title":"Nephrology"},{"key":"10.1016\/j.jaut.2018.11.001_bib214","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1191\/096120300680198935","article-title":"Cyclosporine for lupus membranous nephritis: experience with ten patients and review of the literature","volume":"9","author":"Hallegua","year":"2000","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2018.11.001_bib215","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1681\/ASN.2008060665","article-title":"Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy","volume":"20","author":"Austin","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.jaut.2018.11.001_bib216","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1111\/j.1600-6143.2011.03763.x","article-title":"The PROMISE study: a phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de Novo kidney transplantation","volume":"11","author":"Busque","year":"2011","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.jaut.2018.11.001_bib217","doi-asserted-by":"crossref","first-page":"A2","DOI":"10.1053\/j.ajkd.2017.03.008","article-title":"Treatment of active Lupus nephritis with Voclosporin: 48 week data from the aura-LV study","volume":"69","author":"Parikh","year":"2017","journal-title":"Am. J. Kidney Dis. Conf. Natl. Kidney Found."},{"key":"10.1016\/j.jaut.2018.11.001_bib218","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.semarthrit.2014.04.002","article-title":"Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review","volume":"44","author":"Cobo-Ib\u00e1\u00f1ez","year":"2015","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.jaut.2018.11.001_bib219","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1631\/jzus.B1200057","article-title":"Efficacy and safety of rituximab therapy for systemic lupus erythematosus: a systematic review and meta-analysis","volume":"13","author":"Lan","year":"2012","journal-title":"J. Zhejiang Univ. Sci. B."},{"key":"10.1016\/j.jaut.2018.11.001_bib220","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2018.11.001_bib221","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"LUNAR Investigator Group, Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2018.11.001_bib222","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/s10165-009-0213-x","article-title":"A perspective on B-cell-targeting therapy for SLE","volume":"20","author":"John Looney","year":"2010","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.jaut.2018.11.001_bib223","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/ard.2007.079418","article-title":"B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response","volume":"67","author":"Cambridge","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2018.11.001_bib224","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nrrheum.2016.18","article-title":"The BAFFling effects of rituximab in lupus: danger ahead?","volume":"12","author":"Ehrenstein","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.jaut.2018.11.001_bib225","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/art.38074","article-title":"Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus","volume":"65","author":"Carter","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2018.11.001_bib226","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jaut.2018.03.003","article-title":"The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus","volume":"91","author":"Kraaij","year":"2018","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2018.11.001_bib227","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2018-eular.5711","article-title":"FRI0305 Phase 2 trial of induction therapy with anti-cd20 (RITUXIMAB) followed by maintenance therapy with anti-baff (BELIMUMAB) in patients with active lupus nephritis","volume":"77","author":"Aranow","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2018.11.001_bib228","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/nri2572","article-title":"Cracking the BAFF code","volume":"9","author":"MacKay","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jaut.2018.11.001_bib229","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12013-008-9036-1","article-title":"The BLyS family: toward a molecular understanding of B cell homeostasis","volume":"53","author":"Treml","year":"2009","journal-title":"Cell Biochem. Biophys."},{"key":"10.1016\/j.jaut.2018.11.001_bib230","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1002\/art.37995","article-title":"Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials","volume":"65","author":"Petri","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2018.11.001_bib231","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1084\/jem.20062567","article-title":"BAFF and MyD88 signals promote a lupuslike disease independent of T cells","volume":"204","author":"Groom","year":"2007","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jaut.2018.11.001_bib232","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2018.11.001_bib233","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2018.11.001_bib234","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1136\/annrheumdis-2011-200937","article-title":"Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response","volume":"71","author":"Van Vollenhoven","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2018.11.001_bib235","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti\u2013interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthr. Rheumatol."},{"key":"10.1016\/j.jaut.2018.11.001_bib236","unstructured":"AstraZeneca, Update on TULIP 1 Phase III Trial for Anifrolumab in Systemic Lupus Erythematosus, (n.d.). https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2018\/update-on-tulip-1-phase-iii-trial-for-anifrolumab-in-systemic-lupus-erythematosus-31082018.html."},{"key":"10.1016\/j.jaut.2018.11.001_bib237","doi-asserted-by":"crossref","first-page":"9358","DOI":"10.1074\/jbc.C600321200","article-title":"STAT3 regulates cytokine-mediated generation of inflammatory helper T cells","volume":"282","author":"Yang","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jaut.2018.11.001_bib238","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1182\/blood-2011-11-392985","article-title":"Functional STAT3 deficiency compromises the generation of human T follicular helper cells","volume":"119","author":"Ma","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2018.11.001_bib239","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/ni.3054","article-title":"Pathophysiology of T follicular helper cells in humans and mice","volume":"16","author":"Ueno","year":"2015","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jaut.2018.11.001_bib240","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.humimm.2016.06.007","article-title":"Effect of IL6 and IL23 on double negative T cells and anti ds-DNA in systemic lupus erythematosus patients","volume":"77","author":"Shaltout","year":"2016","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.jaut.2018.11.001_bib241","doi-asserted-by":"crossref","first-page":"903","DOI":"10.4049\/jimmunol.1700418","article-title":"IL-23 limits the production of IL-2 and promotes autoimmunity in lupus","volume":"199","author":"Dai","year":"2017","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2018.11.001_bib242","article-title":"S7A:8 Efficacy and safety of ustekinumab, an interleukin 12\/23 inhibitor, in patients with active systemic lupus erythematosus: results of a phase 2, randomised placebo-controlled study","volume":"5","author":"van Vollenhoven","year":"2018","journal-title":"Lupus Sci. Med."},{"key":"10.1016\/j.jaut.2018.11.001_bib243","first-page":"1","article-title":"Translational and clinical advances in JAK-STAT biology: the present and future of jakinibs","author":"Gadina","year":"2018","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.jaut.2018.11.001_bib244","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Wallace","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2018.11.001_bib245","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1002\/art.23047","article-title":"Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial","volume":"56","author":"Dall'Era","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2018.11.001_bib246","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/art.40360","article-title":"Efficacy and safety of atacicept in patients with systemic lupus erythematosus: results of a twenty-four\u2013week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm, phase IIb study","volume":"70","author":"Merrill","year":"2018","journal-title":"Arthr. Rheumatol."},{"key":"10.1016\/j.jaut.2018.11.001_bib247","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1177\/0961203307086267","article-title":"Improving the prognosis of SLE without prescribing lupus drugs and the primary care paradox","volume":"17","author":"Wallace","year":"2008","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2018.11.001_bib248","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jaad.2009.12.053","article-title":"Photoprotective effects of a broad-spectrum sunscreen in ultraviolet-induced cutaneous lupus erythematosus: a randomized, vehicle-controlled, double-blind study","volume":"64","author":"Kuhn","year":"2011","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jaut.2018.11.001_bib249","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3899\/jrheum.080212","article-title":"Fibromyalgia, systemic lupus erythematosus (SLE), and evaluation of SLE activity","volume":"36","author":"Wolfe","year":"2009","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jaut.2018.11.001_bib250","first-page":"40","article-title":"Fibromyalgia prevalence and related factors in a large registry of patients with systemic lupus erythematosus","volume":"34","author":"Torrente-Segarra","year":"2016","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.jaut.2018.11.001_bib251","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1056\/NEJMoa0912611","article-title":"A randomized trial of tai chi for fibromyalgia","volume":"363","author":"Wang","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2018.11.001_bib252","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/j.2040-4603.2013.tb00485.x","article-title":"The influence of exercise on cognitive abilities","volume":"3","author":"Gomez-Pinilla","year":"2013","journal-title":"Compr. Physiol."},{"key":"10.1016\/j.jaut.2018.11.001_bib253","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/rheumatology\/keg289","article-title":"Fatigue in systemic lupus erythematosus: a randomized controlled trial of exercise","volume":"42","author":"Tench","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaut.2018.11.001_bib254","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2017.05.008","article-title":"Cardiovascular disease in systemic lupus erythematosus: a comprehensive update","volume":"82","author":"Giannelou","year":"2017","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2018.11.001_bib255","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/S0140-6736(96)03032-2","article-title":"Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus","volume":"348","author":"Petri","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2018.11.001_bib256","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1001\/jama.288.16.2015","article-title":"Homocysteine and risk of ischemic heart disease and stroke","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jaut.2018.11.001_bib257","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.4065\/83.11.1203","article-title":"Homocysteine level and coronary heart disease incidence: a systematic review and meta-analysis","volume":"83","author":"Humphrey","year":"2016","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.jaut.2018.11.001_bib258","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.jacc.2011.05.028","article-title":"Homocysteine and reclassification of cardiovascular disease risk","volume":"58","author":"Veeranna","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.jaut.2018.11.001_bib259","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1159\/000101471","article-title":"Podocyte injury and glomerulosclerosis in hyperhomocysteinemic rats","volume":"27","author":"Yi","year":"2007","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.jaut.2018.11.001_bib260","first-page":"80","article-title":"Homocysteine in renal injury","volume":"2","author":"Long","year":"2016","journal-title":"Kidney Dis. (Basel, Switzerland)"},{"key":"10.1016\/j.jaut.2018.11.001_bib261","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2017-eular.6705","article-title":"Homocysteine, antiphospholipid antibodies and risk of vascular events in patients with systemic lupus erythematosus [Abstract]","volume":"76","author":"Stojan","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2018.11.001_bib262","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/00005792-198409000-00001","article-title":"Complement deficiency states and infection: epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency","volume":"63","author":"Ross","year":"1984","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jaut.2018.11.001_bib263","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1177\/0961203313493032","article-title":"Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies","volume":"22","author":"Danza","year":"2013","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2018.11.001_bib264","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2015-000098","article-title":"Risk factors for osteoporosis and fragility fractures in patients with systemic lupus erythematosus","volume":"3","author":"Carli","year":"2016","journal-title":"Lupus Sci. Med."},{"key":"10.1016\/j.jaut.2018.11.001_bib265","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1097\/MED.0000000000000197","article-title":"Systemic lupus erythematosus, bone health, and osteoporosis","volume":"22","author":"Edens","year":"2015","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"10.1016\/j.jaut.2018.11.001_bib266","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1191\/0961203305lu2154oa","article-title":"High prevalence of vertebral deformity in premenopausal systemic lupus erythematosus patients","volume":"14","author":"Borba","year":"2005","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2018.11.001_bib267","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/art.40137","article-title":"2017 American college of rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"69","author":"Buckley","year":"2017","journal-title":"Arthr. Rheumatol."},{"key":"10.1016\/j.jaut.2018.11.001_bib268","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/JAHA.116.003815","article-title":"Calcium intake from diet and supplements and the risk of coronary artery calcification and its progression among older adults: 10-year follow-up of the multi-ethnic study of atherosclerosis (MESA)","volume":"5","author":"Anderson","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.jaut.2018.11.001_bib269","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.93009","article-title":"Single cell RNA sequencing to dissect the molecular heterogeneity in lupus nephritis","volume":"2","author":"Der","year":"2017","journal-title":"JCI Insight"}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841118305213?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841118305213?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T08:20:50Z","timestamp":1760257250000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841118305213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":269,"alternative-id":["S0896841118305213"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2018.11.001","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic lupus erythematosus: Diagnosis and clinical management","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2018.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}